Overview
Autosomal recessive spastic paraplegia type 53 (SPG53) is an extremely rare inherited neurological condition that primarily affects the nervous system, leading to progressive stiffness and weakness in the legs. It is caused by mutations in the VPS37A gene, which plays a role in how cells sort and transport proteins. When this gene does not work properly, nerve cells — especially the long nerve fibers that control leg movement — gradually become damaged. The condition typically begins in early childhood. Children may show delayed motor milestones, such as difficulty learning to walk. Over time, the legs become increasingly stiff (spastic), and walking becomes more difficult. Many affected individuals also experience intellectual disability, which can range from mild to moderate. Some patients may develop additional features such as problems with fine motor skills, speech difficulties, or changes in the structure of the brain visible on MRI. There is currently no cure for SPG53. Treatment focuses on managing symptoms and improving quality of life. Physical therapy, stretching exercises, and medications to reduce muscle stiffness (such as baclofen or tizanidine) are commonly used. Occupational therapy and speech therapy may also be helpful. Because this condition is so rare, much of the medical knowledge comes from a small number of reported families, and research is ongoing to better understand the disease and develop new treatments.
Also known as:
Key symptoms:
Progressive leg stiffness (spasticity)Difficulty walkingDelayed motor milestonesIntellectual disabilityWeakness in the legsExaggerated reflexesDifficulty with fine motor skillsSpeech difficultiesAbnormal gait or walking patternBrain abnormalities on MRI (such as thin corpus callosum)Foot deformities (such as high arches or turned-in feet)
Clinical phenotype terms (16)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Autosomal recessive spastic paraplegia type 53.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal recessive spastic paraplegia type 53 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Autosomal recessive spastic paraplegia type 53.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal recessive spastic paraplegia type 53.
Community
No community posts yet. Be the first to share your experience with Autosomal recessive spastic paraplegia type 53.
Start the conversation →Latest news about Autosomal recessive spastic paraplegia type 53
No recent news articles for Autosomal recessive spastic paraplegia type 53.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is my child's condition based on current testing, and what can we expect over time?,What therapies should we start right away to help maintain mobility?,Are there any medications that could help with the leg stiffness?,Should other family members be tested to see if they are carriers?,Are there any clinical trials or research studies we could participate in?,What educational supports should we put in place for my child?,How often should we schedule follow-up visits and what should we watch for at home?
Common questions about Autosomal recessive spastic paraplegia type 53
What is Autosomal recessive spastic paraplegia type 53?
Autosomal recessive spastic paraplegia type 53 (SPG53) is an extremely rare inherited neurological condition that primarily affects the nervous system, leading to progressive stiffness and weakness in the legs. It is caused by mutations in the VPS37A gene, which plays a role in how cells sort and transport proteins. When this gene does not work properly, nerve cells — especially the long nerve fibers that control leg movement — gradually become damaged. The condition typically begins in early childhood. Children may show delayed motor milestones, such as difficulty learning to walk. Over time
How is Autosomal recessive spastic paraplegia type 53 inherited?
Autosomal recessive spastic paraplegia type 53 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autosomal recessive spastic paraplegia type 53 typically begin?
Typical onset of Autosomal recessive spastic paraplegia type 53 is childhood. Age of onset can vary across affected individuals.